Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Cancer|November 1, 1987
A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG studyG Falkson, L M Ryan, L A Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomasE C Borden, D A Amato, C Rosenbaum, et al.
The New England Journal of Medicine|March 26, 1992
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancerR R Love, R B Mazess, H S Barden, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot studyG Falkson, D Von Hoff, D Klaassen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 13, 2001
Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplantsP P Carbone, J D Pirsch, J P Thomas, et al.
Cancer|January 15, 1980
Nodular mixed lymphocytic-histiocytic lymphoma (NM): response and survival. Eastern Cooperative Oncology GroupE Z Ezdinli, W G Costello, F Icli, et al.
Cancer|September 1, 1976
Combination chemotherapy of the malignant lymphomas: a controlled clinical trialR E Lenhard, R L Prentice, A H Owens, et al.
Cancer|January 1, 1986
A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effectsR S Witte, B Pruitt, D C Tormey, et al.
Cancer Treatment Reports|January 1, 1979
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474)D F Chiuten, J M Bennett, R H Creech, et al.
Annals of Internal Medicine|May 1, 1980
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer InstituteV T DeVita, R M Simon, S M Hubbard, et al.
Pageof 10